Traitement par erlotinib après une toxicité hépatique induite par le géfitinib: revue de la littérature à propos d'une observation = Treatment with Erlotinib after Gefitinib Induced Hepatotoxicity: Literature Review and Case ReportDURAND, Marjorie; LOGEROT, Sophie; FONROSE, Xavier et al.Thérapie (Paris). 2014, Vol 69, Num 2, pp 163-168, issn 0040-5957, 6 p.Article

Significant increase in hEGF uptake is correlated with formation of EGFR dimers induced by the EGFR tyrosine kinase inhibitor gefitinibPENG HE; GANG LI.Cancer chemotherapy and pharmacology. 2013, Vol 72, Num 2, pp 341-348, issn 0344-5704, 8 p.Article

Discovery of 6-substituted 4-anilinoquinazolines with dioxygenated rings as novel EGFR tyrosine kinase inhibitorsLI, Dong-Dong; FEI FANG; LI, Jing-Ran et al.Bioorganic & medicinal chemistry letters (Print). 2012, Vol 22, Num 18, pp 5870-5875, issn 0960-894X, 6 p.Article

Development of erlotinib derivatives as CIP2A-ablating agents independent of EGFR activityCHEN, Kuen-Feng; PAO, Kuan-Chuan; SU, Jung-Chen et al.Bioorganic & medicinal chemistry. 2012, Vol 20, Num 20, pp 6144-6153, issn 0968-0896, 10 p.Article

Discovery of novel EGFR tyrosine kinase inhibitors by structure-based virtual screeningSIYUAN LI; XIANQIANG SUN; HONGLI ZHAO et al.Bioorganic & medicinal chemistry letters (Print). 2012, Vol 22, Num 12, pp 4004-4009, issn 0960-894X, 6 p.Article

Development of [¹¹C]erlotinib Positron Emission Tomography for In Vivo Evaluation of EGF Receptor Mutational StatusBAHCE, Idris; SMIT, Egbert F; LAMMERTSMA, Adriaan A et al.Clinical cancer research (Print). 2013, Vol 19, Num 1, pp 183-193, issn 1078-0432, 11 p.Article

c-Src Activation Mediates Erlotinib Resistance in Head and Neck Cancer by Stimulating c-MetSTABILE, Laura P; GUOQING HE; YAN LUI, Vivian Wai et al.Clinical cancer research (Print). 2013, Vol 19, Num 2, pp 380-392, issn 1078-0432, 13 p.Article

EGFR Protein Expression in Non-Small Cell Lung Cancer Predicts Response to an EGFR Tyrosine Kinase Inhibitor―A Novel Antibody for Immunohistochemistry or AQUA TechnologyMASCAUX, Celine; WYNES, Murry W; NAGAO, Toshitaka et al.Clinical cancer research (Print). 2011, Vol 17, Num 24, pp 7796-7807, issn 1078-0432, 12 p.Article

A Phase I, Pharmacokinetic, and Pharmacodynamic Study of Panobinostat, an HDAC Inhibitor, Combined with Erlotinib in Patients with Advanced Aerodigestive Tract TumorsGRAY, Jhanelle E; HAURA, Eric; TETTEH, Leticia et al.Clinical cancer research (Print). 2014, Vol 20, Num 6, pp 1644-1655, issn 1078-0432, 12 p.Article

Effect of Intermittent Dosing Regimens of Erlotinib on Methylnitrosourea-Induced Mammary CarcinogenesisLUBET, Ronald A; SZABO, Eva; IWATA, Kenneth K et al.Cancer prevention research (Philadelphia, Pa.). 2013, Vol 6, Num 5, pp 448-454, issn 1940-6207, 7 p.Article

Disease Flare after Tyrosine Kinase Inhibitor Discontinuation in Patients with EGFR-Mutant Lung Cancer and Acquired Resistance to Erlotinib or Gefitinib: Implications for Clinical Trial DesignCHAFT, Jamie E; OXNARD, Geoffrey R; SIMA, Camelia S et al.Clinical cancer research (Print). 2011, Vol 17, Num 19, pp 6298-6303, issn 1078-0432, 6 p.Article

Epidermal growth factor receptor (EGFR) exon 20 mutations in non-small-cell lung cancer and resistance to EGFR-tyrosine kinase inhibitorsHYUN SUN WOO; HEE KYUNG AHN; EUN KYUNG CHO et al.Investigational new drugs. 2014, Vol 32, Num 6, pp 1311-1315, issn 0167-6997, 5 p.Article

Preclinical Pharmacokinetic/Pharmacodynamic Models to Predict Schedule-Dependent Interaction Between Erlotinib and GemcitabineMENGYAO LI; HANQING LI; XIAOLIANG CHENG et al.Pharmaceutical research. 2013, Vol 30, Num 5, pp 1400-1408, issn 0724-8741, 9 p.Article

USP8 Is a Novel Target for Overcoming Gefitinib Resistance in Lung CancerBYUN, Sanguine; LEE, Sung-Young; BODE, Ann M et al.Clinical cancer research (Print). 2013, Vol 19, Num 14, pp 3894-3904, issn 1078-0432, 11 p.Article

The effect of rifampicin, a prototypical CYP3A4 inducer, on erlotinib pharmacokinetics in healthy subjectsHAMILTON, Marta; WOLF, Julie L; DROLET, Daniel W et al.Cancer chemotherapy and pharmacology. 2014, Vol 73, Num 3, pp 613-621, issn 0344-5704, 9 p.Article

High EGFR Gene Copy Number and Skin Rash as Predictive Markers for EGFR Tyrosine Kinase Inhibitors in Patients with Advanced Squamous Cell Lung CarcinomaLEE, Youngjoo; HYO SUP SHIM; MOO SUK PARK et al.Clinical cancer research (Print). 2012, Vol 18, Num 6, pp 1760-1768, issn 1078-0432, 9 p.Article

Everolimus synergizes with gefitinib in non-small-cell lung cancer cell lines resistant to epidermal growth factor receptor tyrosine kinase inhibitorsSONG DONG; ZHANG, Xu-Chao; HUA CHENG et al.Cancer chemotherapy and pharmacology. 2012, Vol 70, Num 5, pp 707-716, issn 0344-5704, 10 p.Article

Effects of pemetrexed, gefitinib, and their combination on human colorectal cancer cellsGUANZHONG ZHANG; XIAODONG XIE; TIANYI LIU et al.Cancer chemotherapy and pharmacology. 2013, Vol 72, Num 4, pp 767-775, issn 0344-5704, 9 p.Article

Evaluation of gefitinib efficacy according to body surface area in patients with non-small cell lung cancer harboring an EGFR mutationIGAWA, Satoshi; KASAJIMA, Masashi; KATONO, Ken et al.Cancer chemotherapy and pharmacology. 2014, Vol 74, Num 5, pp 939-946, issn 0344-5704, 8 p.Article

Phase I dose escalation study of capecitabine and erlotinib concurrent with radiation in locally advanced pancreatic cancerYIXING JIANG; MACKLEY, Heath B; KIMCHI, Eric T et al.Cancer chemotherapy and pharmacology. 2014, Vol 74, Num 1, pp 205-210, issn 0344-5704, 6 p.Article

The insulin-like growth factor 1 receptor causes acquired resistance to erlotinib in lung cancer cells with the wild-type epidermal growth factor receptorSUDA, Kenichi; MIZUUCHI, Hiroshi; SATO, Katsuaki et al.International journal of cancer (Print). 2014, Vol 135, Num 4, pp 1002-1006, issn 0020-7136, 5 p.Article

Dose escalation to rash for erlotinib plus gemcitabine for metastatic pancreatic cancer: the phase II RACHEL studyVAN CUTSEM, E; LI, C.-P; LIPP, R et al.British journal of cancer. 2014, Vol 111, Num 11, pp 2067-2075, issn 0007-0920, 9 p.Article

A phase II study of intra-arterial cisplatin with concurrent radiation and erlotinib for locally advanced head and neck cancerRAO, Krishna; KALAPURAKAL, Sini; CHALASANI, Pratima et al.Cancer chemotherapy and pharmacology. 2013, Vol 72, Num 3, pp 545-552, issn 0344-5704, 8 p.Article

Activity of the MEK inhibitor selumetinib (AZD6244; ARRY-142886) in nasopharyngeal cancer cell linesMA, Brigette B. Y; LUI, Vivian W. Y; SAI WAI TSAO et al.Investigational new drugs. 2013, Vol 31, Num 1, pp 30-38, issn 0167-6997, 9 p.Article

Inhibiting proliferation of gefitinib-resistant, non-small cell lung cancerSUDO, Makoto; TAN MIN CHIN; MORI, Seiichi et al.Cancer chemotherapy and pharmacology. 2013, Vol 71, Num 5, pp 1325-1334, issn 0344-5704, 10 p.Article